Evidence map›Paper›PMID 41125677›Full record

ArticleScientific reports2025

Serum adropin and miR-21 expression as predictors of endothelial dysfunction in type 2 diabetes mellitus and vascular complications.

Omur Tabak, Sinem Durmus, Abdulhalim Senyigit, Iffet Dogan, Hatice Segmen, Nihat Sayın, Caner Kacmaz, Aykut Oruc, Hafize Uzun

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Omur TabakDepartment of Internal Medicine, University of Health Sciences, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, 34303, Turkey. omurtabak@yahoo.com.tr.
Sinem DurmusFaculty of Medicine, Department of Medical Biochemistry, İzmir Katip Çelebi University, Izmir, Turkey.
Abdulhalim SenyigitFaculty of Medicine, Department of Internal Medicine, Istanbul Atlas University, Istanbul, Turkey.
Iffet DoganDepartment of Radiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.
Hatice SegmenDepartment of Neurology, University of Health Sciences, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey.
Nihat SayınDepartment of Ophtalmology, University of Health Sciences, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey.
Caner KacmazDepartment of Cardiology, University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.
Aykut OrucCerrahpasa Faculty of Medicine, Department of Physiology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Hafize UzunFaculty of Medicine, Department of Biochemistry, Istanbul Atlas University, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adropin is a peptide involved in the regulation of glycolipid metabolism, contributing to improved glucose homeostasis and the mitigation of dyslipidemia. The objective of this study is to ascertain whether there is a discrepancy in the expression of microRNA-21 (miRNA-21) and adropin levels in Type 2 diabetes mellitus (T2DM) patients who also exhibit macro- and micro-vascular complications (nephropathy, neuropathy, retinopathy) were also observed to uncomplicated diabetes patients and healthy individuals; to explore the relationship between serum adropin and miR-21, endothelial dysfunction, and carotid intima-media thickness (CIMT). The present study comprised 89 patients with T2DM (microvascular n = 24, macrovascular n = 20, uncomplicated type 2 n = 45) and 19 non-diabetic coronary artery disease (CAD). The control group was composed of 20 healthy individuals. Expression of miRNA-21 in all diabetic patients was significantly higher than control group, while adropin levels were found to be significantly lower. No significant difference was observed between the diabetic patient groups with microvascular complications and those without complications regarding miRNA-21 and adropin levels. The miR-21 expression and adropin levels of the non-complicated diabetic group and only the coronary disease group were significantly higher and lower than the control group. CIMT was significantly higher in patients with macrovascular complications and non-diabetic CAD than in the other groups. A positive correlation was found between miR-21 and CIMT, whereas a moderate negative correlation was detected between miR-21 and adropin levels. The present study indicated that adropin and miR-21 can be equally good markers both in separating diabetic patients with macrovascular complications from the healthy group. In the meantime, the endothelial cell is an important target, and endothelial dysfunction is important in diabetic vasculature. Increased miR-21 expression and decreased adropin levels can be explained by the damage that hyperglycemia causes to the endothelium in diabetic patients.

Indexed as

Diabetes Mellitus, Type 2Diabetic AngiopathiesEndothelium, VascularIntercellular Signaling Peptides and ProteinsMicroRNAsPeptidesAdultAgedBiomarkersBlood ProteinsCarotid Intima-Media ThicknessCase-Control StudiesFemaleHumansMaleMiddle AgedBiomarkersBlood ProteinsEnho protein, humanIntercellular Signaling Peptides and ProteinsMicroRNAsMIRN21 microRNA, humanPeptidesAdropinMacrovascular complicationsMicrovascular complicationsMiR-21Type 2 diabetes mellitus

Identifiers

PMID41125677
PMCPMC12546821

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.